Value through Innovation31 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

- For NON-US Media Only

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only

Boehringer Ingelheim on growth path - Successful 2011 financial year


GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

- For media outside of the U.S.A. only

First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate

- For media outside of the U.S.A. only

Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation

- For NON-US and NON-UK Media Only

Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin

- For Non-US, UK & Canadia Media Only

Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1

- For NON-US, NON-UK & NON- Canadian Healthcare Media Only

Boehringer Ingelheim sets up its first Asian Veterinary Research & Development Center in Shanghai


Porcine circovirus research projects from France and Spain awarded


Boehringer Ingelheim expands capabilities in biopharmaceutical process science


Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies


Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration


FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes

- For Non-U.S. and Non-UK Media

Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply